-
1 week ago | 
hcplive.com | Tim Smith
Few medical subfields have witnessed as much of a transformation in both therapeutic innovation and patient-centered care as dermatology, and this especially true in the realm of atopic dermatitis. While the inflammatory condition was once managed using limited topical agents and immunosuppressants, atopic dermatitis treatment has entered an era involving a deeper understanding of immune pathways and molecular targets.
-
1 week ago | 
hcplive.com | Tim Smith
With many different clinicians, researchers, and industry leaders convening in San Francisco, the American Thoracic Society (ATS) 2025 International Conference once again solidified its status as a cornerstone event in the field of pulmonology.
-
2 weeks ago | 
hcplive.com | Tim Smith
In a recent case series presented at the American Thoracic Society (ATS) 2025 International Conference in San Francisco, dupilumab (Dupixent) treatment has been shown to be safe and generally well-tolerated in patients with chronic obstructive pulmonary disease (COPD) and elevated eosinophil counts.1The data, suggesting that dupilumab’s utilization was linked to fewer exacerbations and improvement in patients COPD symptom, as suggested by patient-reported outcomes.
-
2 weeks ago | 
hcplive.com | Tim Smith
The US Food and Drug Administration (FDA) has approved roflumilast (Zoryve) foam 0.3% as a once-daily topical treatment for plaque psoriasis in adults and adolescents aged 12 years and older.1The approval of the non-steroidal psoriasis therapeutic option on May 22, 2025 was announced by Arcutis Biotherapeutics, Inc., addressing the needs of the approximately 9 million individuals within the US who are known to be living with psoriasis.
-
2 weeks ago | 
hcplive.com | Tim Smith
Prenatal exposure to different microplastic particles may impact the neonatal gut microbiome in a manner that increases individuals’ risk of asthma, new findings suggest, and this impact is transmissible through live microbiota.
-
2 weeks ago | 
hcplive.com | Tim Smith
In new post-hoc findings presented at the American Thoracic Society (ATS) 2025 International Conference, a phase 2a study assessing investigational taladegib (ENV-101) therapy for idiopathic pulmonary fibrosis (IPF) demonstrated the first clinical evidence of an IPF therapy leading to a pulmonary vessel volume reduction.1,2 These data, also announced by Endeavor BioMedicines, highlighted notable improvements in imaging-based markers among individuals who had been treated with taladegib over...
-
2 weeks ago | 
hcplive.com | Tim Smith
A new analysis suggests that, unlike dupilumab, rademikibart does not cause eosinophil elevation in patients with asthma, highlighting a potential distinction in how the 2 biologics interact with interleukin (IL)-4Rα.1These findings were presented in a poster session at the American Thoracic Society (ATS) International Conference in San Francisco.
-
2 weeks ago | 
hcplive.com | Tim Smith
In new phase 3 findings from the FIBRONEER-IPF and FIBRONEER-ILD studies, nerandomilast met its primary endpoint in both studies evaluating responses in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).1 These late-breaking data, announced at the American Thoracic Society (ATS) International Conference in San Francisco, were detailed in a release by Boehringer Ingelheim that highlights the phase 3 findings on nerandomilast, an investigational oral,...
-
2 weeks ago | 
hcplive.com | Tim Smith
Rademikibart treatment of asthma leads to rapid lung function improvements within 24 hours of the first dose, according to recent findings, and these improvements are sustained over time.1These findings, highlighting rademikibart’s potential as a fast-acting therapeutic option for individuals with type 2 inflammation, were presented at the 2025 American Thoracic Society (ATS) International Conference in San Francisco.
-
2 weeks ago | 
hcplive.com | Tim Smith
Dupilumab therapy for patients living with severe asthma leads to long-lasting improvements in lung function, asthma control, quality of life, and exacerbation reductions, new findings suggest, with remission being observed in over half of those treated within 1 to 2 years.1 This data were presented at the American Thoracic Society (ATS) International Conference in the poster titled ‘Severe Asthma After 2 Years of Dupilumab Therapy: Real-world Data From the ProVENT Study.’ The research was...
